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Abstract
Background: Skeletal muscle mass is controlled by myostatin and Akt-dependent signaling on mammalian target of
rapamycin (mTOR), glycogen synthase kinase 3b (GSK3b) and forkhead box O (FoxO) pathways, but it is unknown how these
pathways are regulated in critically ill human muscle. To describe factors involved in muscle mass regulation, we
investigated the phosphorylation and expression of key factors in these protein synthesis and breakdown signaling
pathways in thigh skeletal muscle of critically ill intensive care unit (ICU) patients compared with healthy controls.
Methodology/Principal Findings: ICU patients were systemically inflamed, moderately hyperglycemic, received insulin
therapy, and showed a tendency to lower plasma branched chain amino acids compared with controls. Using Western
blotting we measured Akt, GSK3b, mTOR, ribosomal protein S6 kinase (S6k), eukaryotic translation initiation factor 4E
binding protein 1 (4E-BP1), and muscle ring finger protein 1 (MuRF1); and by RT-PCR we determined mRNA expression of,
among others, insulin-like growth factor 1 (IGF-1), FoxO 1, 3 and 4, atrogin1, MuRF1, interleukin-6 (IL-6), tumor necrosis
factor a (TNF-a) and myostatin. Unexpectedly, in critically ill ICU patients Akt-mTOR-S6k signaling was substantially higher
compared with controls. FoxO1 mRNA was higher in patients, whereas FoxO3, atrogin1 and myostatin mRNAs and MuRF1
protein were lower compared with controls. A moderate correlation (r
2=0.36, p,0.05) between insulin infusion dose and
phosphorylated Akt was demonstrated.
Conclusions/Significance: We present for the first time muscle protein turnover signaling in critically ill ICU patients, and we
show signaling pathway activity towards a stimulation of muscle protein synthesis and a somewhat inhibited proteolysis.
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Introduction
Skeletal muscle, which constitutes 30–40% of human body
weight [1], is critical for numerous functions such as breathing,
locomotion and metabolism, and this most abundant tissue also
serves as a large protein reservoir. Loss of muscle mass is a
hallmark of various diagnoses like cancer, chronic heart failure,
chronic obstructive pulmonary disease and HIV-infection, and
weight loss or low fat free mass independently predicts mortality in
these conditions [2,3]. Likewise, debilitating muscle atrophy is part
of critical illness [4,5,6,7,8] occurring at a mean rate of 3–4% of
fiber cross-sectional area per day [5]. Skeletal muscle mass is
regulated through the balance between the rates of protein
synthesis and protein breakdown. The signaling pathways
mediating this balance include, but are not limited to, the Akt-
mTOR, Akt-GSK3b, Akt-FoxO and the myostatin pathways
[9,10,11]. Akt (aka protein kinase B) is activated by insulin and
IGF-1 and has two known major downstream branches relevant to
muscle protein synthesis: the mTOR pathway, which is activated
by Akt, and the GSK3b pathway, which is inhibited by Akt.
mTOR seems to be a key regulator of cell size and protein
synthesis combining signals from growth factors and nutrients
[9,11]. mTOR is comprised of complex1 and 2 (mTORC1 and
mTORC2), and the effect of mTOR on protein synthesis is
mediated through mTORC1 by the activation of S6k and the
inhibition of 4E-BP1. Akt also phosphorylates and inactivates the
FoxO transcription factor family, which consists of FoxO1, 3, 4
and 6 [9]. The activation of FoxO3 causes muscle loss through
increased proteolysis, and FoxO3 induces the muscle specific
ubiquitin ligases atrogin1/MAFbx (from here on referred to as
atrogin1) and MuRF1 [12,13,14,15]. In fact, muscle that lack
either of these ligases atrophy less upon disuse [16], and atrogin1,
MuRF1 and FoxO1 belong to a set of muscle atrophy-related
genes termed ‘‘atrogenes’’ [17]. The transforming growth factor-b
PLoS ONE | www.plosone.org 1 March 2011 | Volume 6 | Issue 3 | e18090(TGF-b) superfamily member myostatin is another negative
regulator of muscle mass, and the inhibition of myostatin increases
muscle mass, whereas the overexpression of it induces muscle
atrophy [18,19,20].
Accordingly, myostatin and Akt-dependent signaling on
mTOR, GSK3b and FoxO pathways play key roles in the control
of skeletal muscle protein turnover, and animal studies have
examined the role of these pathways in critical illness models
[10,21,22], but it is unknown how these pathways are regulated in
critically ill human muscle. Thus, the aim of our study was to
investigate the Akt-mTOR, Akt-GSK3b and Akt-FoxO signaling
pathways as well as expression of TGF-b members in skeletal
muscle of critically ill ICU patients. We hypothesized that ICU
patients would have higher proteolytic and lower protein synthesis
signaling compared with controls.
Materials and Methods
Subjects and ethics
The experimental group consisted of 12 patients admitted to the
Intensive Care Unit at Bispebjerg Hospital, Copenhagen Univer-
sity Hospital. The control group consisted of 12 age- and sex-
matched healthy, ambulatory controls. Since the transcriptional
profile of human critical illness skeletal muscle agrees poorly with
that of inactivated skeletal muscle [23] the use of ambulatory
controls is justified. Exclusion criteria were being younger than 18
years, pregnant or nursing. Informed and surrogate informed
written consent was obtained from control subjects and relatives to
patients, respectively. The study followed the rules of the
Declaration of Helsinki and was approved by the local ethical
committee of Copenhagen and Frederiksberg municipality (KF 01
260751).
As part of their clinical treatment the ICU patients received
intravenous insulin therapy to control critical illness hyperglyce-
mia, and at the time when they were recruited the local ICU
insulin therapy reflected ‘‘intensive insulin therapy’’ [24,25].
Insulin (Novorapid, Novo Nordisk, Bagsvaerd, Denmark) infusion
was adjusted with the aim of maintaining normoglycemia based on
measurements of whole blood glucose in undiluted arterial blood,
performed at one-to four-hour intervals with the use of a glucose
analyzer (ABL700, Radiometer Medical, Copenhagen, Denmark).
All patients received enteral (Fresubin Original, Fresenius Kabi,
Bad Homburg, Germany) and/or parenteral (StructoKabiven,
Fresenius Kabi) nutrition.
Blood analyses
Blood levels of leukocytes, C-reactive protein (CRP), urea and
creatinine were determined in-house (ISO certified lab), and the
stated numbers derive from measurements at 06:00 A.M. at the
day of the biopsy. Multiplex assays performed according to the
manufacturer’s instructions (HSCYTO60SK or MPXHCYTO-
60K, Milliplex, Millipore, Billerica, MA, USA) were used to
measure levels of the systemic inflammatory markers TNF-a, IL-6,
IL-8, IL-10 and monocyte chemoattractant protein-1 (MCP-1)/
chemokine (C-C motif) ligand 2 (CCL2) in blood sampled at the
time of the biopsy. Blood samples from controls were taken at rest
in the morning. Plasma amino acid concentrations were quantified
by HPLC as described recently by our group [26]. Plasma IGF-1
concentrations were determined by a time-resolved immuno-
fluorometric assay (Perkin Elmer, Turku, Finland) [27].
Muscle biopsies
Muscle biopsies were obtained under local Lidocaine anesthesia
from the vastus lateralis muscle (m. quadriceps femoris) using the
percutaneous needle biopsy technique of Bergstro ¨m [28] with
5 mm biopsy needles and manual suction. On extraction, the
biopsy was divided and immediately frozen in liquid nitrogen.
Biopsies were stored at -80uC pending analyses.
RNA extraction
Approximately 10 mg of frozen muscle tissue was homogenized
in a microvial containing 1 silicium carbide crystal, 5 steel beads
(2.3 mm) and 1000 ml TRI-reagent (Molecular Research Center,
Cincinnati, OH, USA) using a FastPrep-24 (MP Biomedicals,
Solon, OH, USA) homogenizer. Each sample was shaken 3 times
in the homogenizer for 15 s at speed 4 with a 2 min interval
between each run, in which samples were kept in ice-water bath.
Total RNA was extracted according to Chomczynski & Sacchi
[29]. After homogenization, 100 ml 1-bromo-3-chloropropane was
added to separate the samples into an aqueous and an organic
phase. After isolation of the aqueous phase, RNA was precipitated
using isopropanol, washed in ethanol and subsequently dissolved
in RNase-free water. RNA concentrations were measured by
spectroscopy at 260 nm. Good RNA quality was ensured by
spectrophotometer ratios at 260/240 nm (acceptable range 1.2–
1.6 at pH 8) and 260/280 nm and by denaturing agarose gel
electrophoresis.
Reverse transcriptase quantitative PCR (RT-qPCR)
Total RNA (750 ng from each muscle sample) was converted
into cDNA in 20 ml using the OmniScript reverse transcriptase
(Qiagen, Valencia, CA, USA) according to the manufacturer’s
instructions. For each mRNA target, 0.25 or 0.50 ml cDNA was
amplified in a 25 ml SYBR Green PCR reaction containing 1X
Quantitect SYBR Green Master Mix (Qiagen) and 100 nM of
each primer (Table S1). The amplification was monitored real-
time using the MX3005P real-time PCR machine (Stratagene, La
Jolla, CA, USA). The threshold cycle (Ct) values were related to
standard curves made with cloned PCR products to determine the
relative difference between the unknown samples, and the
specificity of the PCR products was confirmed by melting curve
analysis after amplification. Due to limited amount of tissue n
equals 11 in each group for RT-qPCR. TNF-a mRNA was
expressed at low levels and in some samples TNF-a mRNA was
below the detection limit resulting in 0 values. Thus, TNF-a
mRNA was analyzed in quadruplicate to reduce stochastic
variation, and the median raw values were used for non-
parametric statistical analysis. All mRNA data were normalized
to acidic ribosomal protein P0 (RPLP0).
Western blot
Approximately 30 mg of frozen muscle tissue was homogenized
as described for RNA extraction, except that it was done in 500 ml
ice-cold homogenization buffer (50 mM Tris-base, 1 mM EDTA,
1 mM EGTA, 10 mM beta-glycerophosphate, 50 mM sodium
fluoride, 0.5 mM sodium orthovanadate, 0.1% v/v, Triton-X,
0.1% v/v mercaptoethanol and protease inhibitor (Complete,
Roche, Basel, Schwitzerland), pH 7.5). Protein concentrations
were determined with the Bradford assay and equal amounts
(10 mg/10 ml) was added 2 ml 6X Laemmli buffer (62.5 mM Tris-
base (pH 6.8), 2% w/v sodium dodecyl sulphate (SDS), 40% v/v
glycerol, 5% v/v mercaptoethanol and 1 mg/ml bromophenol
blue), heated at 90uC for 4 min, shortly vortexed, spun for 5 s in a
microcentrifuge and separated by SDS-PAGE using a 4-12% Bis-
Tris gel (Criterion, Bio-Rad, Hercules, CA, USA) at 200 V for
1 h. Gels were blotted (Trans-blot cell, Bio-Rad, 400 mA, 2 h) to
polyvinylidene difluoride membranes (Amersham Hybond LFP,
GE Healthcare, Buckinghamshire, UK) in transfer buffer (50 mM
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total and phospho proteins that were transferred without
methanol. Then, membranes were washed (165 min) in Tris-
buffered saline with 0.1% v/v Tween 20 (TBST, pH 7.4), blocked
for 30 min with 20% Odyssey blocking buffer (Li-Cor Biosciences,
Lincoln, NE, USA) in phosphate-buffered saline, washed
(365 min), incubated overnight at 4uC in primary antibody,
washed (365 min), incubated for 1 h in fluorophore-conjugated
secondary antibody, washed (365 min), and visualized with the
Odyssey Infrared Imaging System (Li-Cor Biosciences). All total
and phosphorylated protein pairs, except for mTOR, were
detected simultaneously on the same membrane. Equal loading
was verified by Coomassie staining. Band intensities were
quantified using ImageJ (National Institutes of Health, Bethesda,
MD, USA). For details on antibodies see table S2.
Data presentation and statistical analyses
Data in figures are presented as individual values and means in
scatter plots, whereas data in tables are means 6 standard error of
the mean (SEM). Muscle mRNA and protein data were log-
transformed and are presented as individual values relative to
control mean. Statistical differences between groups were
determined using unpaired, two-tailed, unequal variance Welch’s
t-tests or for TNF-a mRNA Mann-Whitney U test. The
relationship between insulin infusion dose and phosphorylated
Akt was evaluated by linear regression analysis. This is biologically
relevant as Akt is part of the canonical insulin-phosphatidylinositol
3-kinase (PI3K) signaling pathway [30]. Results were considered
significant when p,0.05.
Results
Patient characteristics
ICU patient characteristics are provided in table 1. All patients
required mechanical ventilation at the time of the biopsy. Patients
were 6465 years old, equally represented both sexes and had
diagnoses of pulmonary and/or abdominal origin. 8 patients were
septic and 10 patients had pneumonia and/or respiratory
insufficiency. 5 patients died in the ICU, whereas 7 survived, of
whom one died subsequently at another hospital department
(Table 1).
As specified in table 2, the included patients were, on average,
moderately hyperglycemic at the time of the biopsy (Table 2) as
well as 111622 minutes prior to the biopsy (mean6SEM
9.160.8 mmol/l), and all received insulin therapy to control
hyperglycemia during their ICU stay. All except patient 2 received
insulin (1–10 IU per hour) at the time of the biopsy (Table 2), and
the individual doses were the same 6165 minutes prior to the
biopsy. Patients 5 and 8 had diagnosed type 2 diabetes (T2D),
whereas patient 11 likely had unrecognized T2D. Patient 10 had
type 1 diabetes.
Markers of systemic inflammation, proteins, metabolites
and muscle cytokines
As shown in table 3, ICU patients had circulating levels of
leukocytes, urea and creatinine approximately 2-fold above the
normal range, whereas plasma CRP was increased by more than
10-fold compared to the upper normal range. Patients, who died
had higher CRP levels than surviving patients (p,0.05, Figure 1).
Serum albumin levels were below normal. Moreover, the levels of
the pro-inflammatory cytokines MCP-1, TNF-a, IL-8 and IL-6
were approximately 4, 6, 52 and 170-fold higher in patients
compared with control subjects (p=0.05 for IL-8, p,0.05 for
others, Table 3). This was also the case for the anti-inflammatory
cytokine IL-10, which was more than 40-fold higher in patients
(p,0.05).
Contrary to the high levels of circulating pro-inflammatory
cytokines in patients, the local muscle mRNA levels of TNF-a
(292%, p,0.001) and IL-1b (256%, p,0.05) were lower in
patients than in controls (Figure 2A and Figure S1 left). IL-1b
protein was below our detection limit in plasma, whereas IL-8 and
IL-10 mRNA were below our detection limit in muscle. Muscle
MCP-1 mRNA was not different in patients vs. controls (Figure S1
right). Similar to plasma IL-6 protein, muscle IL-6 mRNA was
235% higher in patients compared with controls (p,0.001,
Figure 2B).
Plasma amino acids
Total plasma amino acids (AA) and essential AA (EAA) were not
different between ICU patients and controls (Figure 3A and B),
whereas branched chain AA (BCAA) tended to be 18% lower in
patients (p=0.09, Figure 3C). The BCAA leucine and valine were
22 (p=0.08) and 21% (p,0.05) lower, respectively, in patients vs.
controls, whereas phenylalanine and proline were 147 and 115%
higher in patients (p,0.05, Table 4).
Akt-mTOR and Akt-GSK3b signaling
Phosphorylated Akt at threonine (T) 308 (p-Akt (T308)) and p-
Akt (T308)/total Akt (Akt) were 146 and 86% higher in ICU
patients compared with controls (p,0.001, Figure 4A middle and
right). Akt was 33% higher in patients (p,0.05, Figure 4A left).
Likewise, p-Akt (serine (S) 473) and p-Akt (S473)/Akt were 187 and
138% higher in patients (p,0.001, Figure 4B middle and right). P-
mTOR (S2448) and p-mTOR (S2448)/mTOR were 254 and
243% higher in ICU patients vs. controls (p,0.001 and 0.01,
Figure 4C middle and right), whereas p-mTOR (S2481) was below
the detection limit. In ICU patients p-S6k (T389) and p-S6k/S6k
were 183 and 160% higher compared with controls (p,0.001 and
0.01, Figure 4D middle and right). 4E-BP1 and p-4E-BP1 (T37/46)
tended to be 46% and was 51% higher compared with controls
(p=0.06 and ,0.05, Figure 4E left and middle), and, accordingly,
p-4E-BP1/4E-BP1 was unchanged (Figure 4E right). GSK3b and
p-GSK3b (S9) tended to be 19 and 26% higher compared with
controls (p=0.08 and 0.07, Figure 4F left and middle), and
accordingly p-GSK3b/GSK3b was unchanged (Figure 4F right).
Muscle IGF-1Ea mRNA and plasma IGF-1 protein were 48 and
43%lowerinICUpatientsvs.controls(p,0.05and0.01,Figure5A
left, Figure 5B and Table 3), while IGF-1Ec (aka mechano growth
factor, MGF) was not different (+52%, p=0.15, Figure 5A right).
Correlation of insulin and Akt phosphorylation
To estimate the role of exogenous insulin in the activation of the
Akt-mTOR-S6k pathway, we correlated the insulin infusion dose
at the time of the biopsy with phosphorylation of Akt at T308,
which represents the upstream activation by 3-phosphoinositide
dependent protein kinase 1 (PDK1). A moderate correlation
(r
2=0.36, p,0.05) between insulin doses and p-Akt (T308) was
demonstrated (Figure 6).
FoxO transcription factors, atrogin1 and MuRF1
FoxO1 mRNA was 310% higher in ICU patients compared
with controls (p,0.001, Figure 7A left), whereas FoxO3 and 4
mRNA were 62 and 83% lower compared with controls (p,0.05
and 0.01, Figure 7A middle and right). FoxO6 mRNA was below
the detection limit. Unfortunately, we could not detect Foxo1, 3
and 4 proteins or any phosphorylation hereof. In ICU patients
atrogin1 mRNA was 43% lower than controls (p,0.01, Figure 7B
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Figure 7B right), whereas MuRF1 protein was 44% lower
compared with controls (p=0.05, Figure 7C).
Myostatin, GDF-11 and TGF-b1
mRNA levels of myostatin, (p,0.001), TGF-b1 and growth
differentiation factor 11 (GDF-11) (p,0.01) were 95, 65 and 52%
lower in ICU patients compared with controls (Figure 8A–C).
Discussion
We present for the first time muscle protein turnover signaling
in critically ill patients, and we show signaling pathway activity in
the direction of a stimulation of muscle protein synthesis and
somewhat inhibited proteolysis. Specifically, we show unexpected
higher Akt-mTOR-S6k signaling and lower FoxO3, atrogene and
myostatin expression in ICU patients vs. controls (Figure 9).
Akt-mTOR and Akt-GSK3b signaling
Surprisingly, in the muscles of systemically inflamed critically ill
ICU patients (Tables 1 and 3) we show substantially higher
phosphorylation of Akt and mTOR including its downstream
targets S6k and 4E-BP1, whereas GSK3b tend to be lower than in
healthy controls (Figure 4A–F). Upon phosphorylation, S6k is
activated, enabling increased protein synthesis, whereas phos-
phorylation of 4E-BP1 releases it from the inhibitory complex with
the translation initiation factor eIF4E, facilitating the binding of
eIF4E to eIF4G and thereby promoting translation initiation
[9,10,11]. An increase in both total and phosphorylated 4E-BP1
(Figure 4E) would thus probably cancel each other out. This
higher Akt-mTOR-S6k signaling was unexpected, since phos-
phorylations at relevant sites of Akt, mTOR, 4E-BP, S6k and
S6k’s downstream substrate ribosomal protein S6 are decreased in
muscles of different animal models of sepsis [10,31,32] and burn
injury [33].
What may cause this higher Akt-mTOR-S6k signaling? IGF-1
and insulin are known activators of Akt-mTOR signaling
[9,10,11], and Akt phosphorylation status was higher in
postmortem rectus abdominis muscle biopsies of intensive insulin
treated ICU patients compared with surgery patient controls [34],
but no further downstream molecules were measured in that study.
Since we in the present study show lower plasma IGF-1 and
Table 1. ICU patient characteristics.
Patient
# Diagnoses Age/sex
ICU days
at biopsy Survival
Days of
ICU stay
Vaso-
pressor
agents Sedation
Synthetic
glucocorticoids
Substance
use Nutrition
1 Thorax trauma,
sepsis
28/M 3 S 22 NA Propofol,
fentanyl
Hydrocortisone
50 mg IV 4/daily
Alcohol,
cannabis,
tobacco
PN+EN
2 Pneumonia,
sepsis, respiratory
insufficiency
71/M 16 S 27 None None None Tobacco
(Alcohol
previously)
EN
3 Intestinal necrosis, sepsis,
respiratory insufficiency
56/F 2 D, day 6 6 NA Propofol,
remifentanil
Hydrocortisone
50 mg IV 4/daily
Alcohol,
tobacco
PN
4 Perforated peptic ulcer,
sepsis, respiratory
insufficiency
90/F 3 D, day 21 21 NA Remifentanil None None PN
5 Pneumonia, respiratory
insufficiency
68/M 3 D, day 7 7 NA Propofol,
remifentanil
None Alcohol,
tobacco
EN
6 Intestinal perforation,
sepsis, respiratory
insufficiency
73/F 17 S 27 NA Fentanyl None Tobacco EN
7 Pneumonia, respiratory
insufficiency
77/F 13 (11)
1 S 41 NA None Prednisolone
37.5 mg PO 1/daily
(Tobacco
previously)
EN
8 Pneumonia, respiratory
insufficiency, cardiac arrest
68/M 7 (5)
1 S 14 NA Propofol,
remifentanil
None Alcohol PN
9 Liver coma, pneumonia,
respiratory insufficiency
61/M 2 D, day 11 11 None None None Alcohol,
tobacco
EN
10 Abdominal abscess, sepsis,
respiratory insufficiency
47/M 1 D, day 2 2 NA, A Propofol,
remifentanil
Hydrocortisone
100 mg IV 4/daily
(Alcohol
previously)
PN
11 Peritonitis, sepsis 71/F 2 S (died day
9a to t h e r
dept.)
3 None Propofol,
remifentanil
None (Tobacco
previously)
EN+PN
12 Cardiac arrest, pneumonia,
sepsis, respiratory
insufficiency
61/F 2 S 4 NA None None Alcohol EN
Mean 6 SEM 64656 621 5 64
Mean 6 SEM controls 6564
ICU days at biopsy: Time spent in the ICU at the time of the muscle biopsy.
1These patients had intermittent stays at other departments: The total days of stay in hospital are stated (numbers in parentheses are days of stay in ICU solely). M: Male,
F: Female, S: Survival, D: Death. NA: Noradrenaline, A: Adrenaline, IV: Intravenous, PO: Peroral, EN: Enteral, PN: Parenteral.
doi:10.1371/journal.pone.0018090.t001
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systemic nor local IGF-1 could be the driving force in the
activation of Akt-mTOR-S6k signaling. To further examine this
question, we estimated the role of exogenous insulin by correlating
insulin infusion dose at the time of the biopsy with Akt
phosphorylated at T308, our most upstream target. We observed
a moderate correlation (Figure 6) demonstrating responsiveness of
Akt T308 phosphorylation in an insulin dose dependent fashion.
Exogenous insulin dose may, however, be of limited value in the
correlation with protein phosphorylation status, as ICU patients
display signs of insulin resistance of varying degrees (Table 2) [35],
and insulin sensitivity apparently increases with insulin therapy in
critical illness [34,36]. Accordingly, it is currently unclear if insulin
therapy activates Akt-mTOR-S6k signaling in ICU patients under
the present study conditions, and whether insulin induces muscle
protein synthesis in critically ill ICU patients similar to what is seen
in ICU burn patients [37].
Alternatively or additionally to insulin, an enhanced S6k
phosphorylation could reflect an increased protein synthesis driven
by the increased availability of intracellular amino acids resulting
from increased proteolysis as shown in burn patients [38]. Amino
acids, especially leucine, are known to stimulate skeletal muscle
protein synthesis via both insulin-dependent and insulin-indepen-
dent mechanisms [39]. Interestingly, S6k phosphorylation is
increased in insulin-unstimulated rat burn injury [21], and we show
a vastly higher S6k phosphorylation (Figure 4D). Since amino acids
activate mTOR partly independent of insulin, and since mTOR
phosphorylates S6k, the authors [21] suggested that increased amino
acidavailabilitycould increaseinsulin-unstimulated proteinsynthesis
through mTOR-S6k independent of Akt. However, it should be
noted that the insulin-dependent mechanism of leucine-enhanced
protein synthesis is associated with increased phosphorylation of S6k
and 4E-BP1 [40] and that the stimulating effectof leucine on protein
synthesis is impaired in animal sepsis [41]. Overall, in our fed ICU
patients compared with post-absorptive controls we observe a very
similar pattern of differences in plasma amino acid concentrations
including lower leucine levels in patients (Table 4) as shown
previously in post-absorptive septic patients compared with healthy
controls [42]. Importantly, lower plasma amino acid concentrations
do not necessarily equal lower muscle intracellular levels [43].
Specifically,lowerplasmaBCAAconcentrationsarenotmirroredby
low muscle levels [43] and in fact burn patients present with higher
muscle leucine but similar plasma levels relative to healthy controls
[38]. Accordingly, the possibility of mTOR specifically and general
protein turnover signaling being affected by nutrients and amino
acids should be considered.
Table 2. ICU patient glucose concentrations and insulin
doses.
Patient #
Blood glucose conc.
at biopsy mmol/l
Insulin dose at
biopsy IU/h Notes
1 10.4 5.0
2 7.0 0.0
3 6.5 7.5
4 8.5 8.0
5 9.1 2.0 T2D
6 7.9 1.5
7 8.3 2.5
8 8.0 10.0 T2D
9 9.7 3.0
10 14.2 5.5 T1D
11 9.3 10.0 T2D
1
12 6.8 1.0
Mean±SEM 8.8±0.6 4.7±1.0
IU: International units, T1D: Type 1 diabetes, T2D: Type 2 diabetes.
1Patient 11 likely had unrecognized T2D.
doi:10.1371/journal.pone.0018090.t002
Table 3. Circulating IGF-1, markers of systemic inflammation, proteins and metabolites.
Variable Control subjects (n=12) ICU patients (n=12) % Difference
IGF-1, mg/l 132614 76614{ 243
Inflammatory markers
Leukocytes, 10
9/l ND, normal range: 3.0–9.0 16.363.3
CRP, mg/l ND, normal ,10 134628
TNF-a, pg/ml 3.960.5 27.368.4* +605
IL-6, pg/ml 6.361.5 10966366* +17371
IL-8, pg/ml 3.860.5 201691
1 +5246
IL-10, pg/ml 13.962.7 6076262* +4258
MCP-1, pg/ml 266628 14386213{ +440
Proteins and metabolites
Serum albumin, g/l ND, normal range: 34–48 21.161.6
Urea, mmol/l ND, normal range: 3.1–8.1 16.964.3
Creatinine, mmol/l ND, normal range: 45–105 160633
All values were measured in plasma, except for leukocytes, which were determined in whole blood.
Values are means 6 SEM. ND: Not determined.
*p,0.05,
{p,0.01,
{p,0.001,
1p=0.05.
doi:10.1371/journal.pone.0018090.t003
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atrophic COPD patients, may also represent an unsuccessful
attempt trying to restore muscle mass [44], which agrees with ICU
patient transcriptome data indicating a sustained protein synthesis
similar to that in healthy controls in concert with a transcription
program unable to compensate for enhanced protein breakdown
[23,45]. A dysfunctional muscle regenerative system is supported
by a tendency (p=0.09) in ICU patients to lower mRNA levels of
tenascin-C (Figure S2), an apparent key regulator of muscle repair
[46].
FoxO transcription factors, atrogin1, MuRF1 and TNF-a
FoxO3 is required for and causes skeletal muscle atrophy
through the ubiquitin-proteasome and autophagic-lysosomal
Figure 1. Higher plasma C-reactive protein levels in non-
surviving than in surviving ICU patients. Data are fold change in
individual values. Each square represents one patient (white: survivors,
black: dead) and the bar represents the mean value. * p,0.05.
doi:10.1371/journal.pone.0018090.g001
Figure 2. Lower TNF-a and higher IL-6 mRNA expression in
muscle of critically ill patients. TNF-a (A) and IL-6 (B) mRNA
expression in thigh skeletal muscle of critically ill intensive care unit
(ICU) patients compared with controls (CON). As TNF-a mRNA was
below the detection limit in some ICU patients (yielding 0 values), TNF-
a mRNA was determined in quadruplicate and the median values for
each group are reported in arbitrary units. IL-6 data are fold change in
individual values relative to control mean. Each circle represents one
subject (black: controls, white: ICU patients) and the bar represents the
median TNF-a or the mean IL-6 value. { p,0.001, Mann-Whitney U test
for TNF-a and Welch’s t-test for IL-6.
doi:10.1371/journal.pone.0018090.g002
Figure 3. Lower branched chain amino acids in plasma of
critically ill patients. Total plasma amino acids (AA) (A), essential
amino acids (EAA) (B) and branched chain amino acids (BCAA) (C) in
critically ill intensive care unit (ICU) patients compared with controls
(CON). Each circle represents one subject (black: controls, white: ICU
patients) and the bar represents the mean value.
doi:10.1371/journal.pone.0018090.g003
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muscle loss FoxO1 mRNA is increased [17,48,49] including
different sepsis models [22,50,51]. Here, we show a differing
response of muscle FoxO1, 3 and 4 in critically ill patients. The
amount of FoxO1 mRNA was more than 3-fold higher, whereas
the amount of FoxO3 and 4 mRNAs were 60–80% lower in
patients vs. controls (Figure 7A). Importantly, this divergent
response of FoxO1, 3 and 4 suggests different functional roles for
the specific FoxO members in human skeletal muscle. To our
knowledge, we here present the first data on FoxO4 mRNA
expression in human skeletal muscle, and we show an 83% lower
expression in muscle of critically ill patients. This is in agreement
with numerous animal studies, as FoxO4 mRNA was unchanged
with corticosteroids and sepsis [49,50,51], but not all, since FoxO4
mRNA increased with glucocorticoids [48]. Activation of FoxO3
induces atrogin1 and MuRF1 transcription [12,14], and these two
ubiquitin ligases are also atrogenes [17]. To our surprise, atrogin1
mRNA and MuRF1 protein were lower in muscle of critically ill
patients (Figure 7B–C), which is in contrast to their upregulation in
several murine models of muscle atrophy [17] and the increased
atrogin1 mRNA expression in septic ICU patients [23]. This
discrepancy prompted us to determine two of the most responsive
genes in that ICU patient study [23], IL-6 receptor (IL-6R) and
actinin3, which were approximately 10 and 6-fold up- and
downregulated, respectively. We found IL-6R to be unchanged,
whereas actinin3 dramatically decreased by 97% (p,0.001, Figure
S3), which demonstrate differences between the two studies. Of
these differences, the fact that control subjects in the study by
Fredriksson et al [23] were patients undergoing elective surgery is
the most striking difference between the two studies.
Different roles of FoxO1 and FoxO3 in insulin and AMPK
signaling have been suggested in previous in vitro non-muscle cell
studies [52,53] and in rat sepsis-induced muscle wasting [51].
Regarding different roles of FoxO isoforms in muscle atrophy,
FoxO3 per se causes atrophy and is sufficient to induce atrogin1
and MuRF1 transcription [12,14], whereas some studies [54,55],
but not all [56], show that FoxO1 is not sufficient to increase
atrogin1 and MuRF1 mRNA expression in muscle cells. Insulin
(or IGF-1) downregulates atrogin1 and to a lesser extent MuRF1
mRNA in vitro [57], and Akt activation mimics this by decreasing
atrogin1 and MuRF1 mRNA expression and inhibits atrophy
[12,54,58]. Accordingly, most of the available in vitro and animal-
derived data on atrogin1 and MuRF1 expression are consistent
with the observed downregulation of atrogin1 and MuRF1 being
due to insulin administration, Akt phosphorylation and FoxO3
downregulation. Moreover, we have recently found a similar
occurrence in human glucose-induced hyperinsulinemia showing
decreased skeletal muscle atrogin1 and MuRF1 mRNA in concert
with increased FoxO1 and unchanged FoxO3 mRNA (Neder-
gaard, Jespersen, Schjerling and Kjaer, unpublished) similar to
results from rats [59]. Additionally, insulin downregulates TNF-a,
but not IL-6 mRNA, in human skeletal muscle in vivo [60].
Accordingly, in the present study it seems likely that lower
atrogene and TNF-a expression in ICU patients is regulated by
the higher Akt phosphorylation and possibly insulin administra-
tion, but this remains to be proven in a more controlled set-up.
Interestingly, similar to the present study, Greenhaff et al [61] in
insulin-clamped healthy, young men, showed a relationship
between increased serum insulin concentration and increased
Akt and S6k phosphorylation as well as decreased atrogin1 protein
levels, which, however, was disassociated with changes in muscle
protein turnover. This may suggest that the magnitude of
phosphorylation of these proteins under conditions of elevated
insulin does not reflect muscle protein synthesis, at least in young,
healthy individuals [61], even though insulin stimulates human
muscle protein synthesis through increased nutritive flow and
mTORC1-S6k signaling [62]. Of note, insulin (and IGF-1)
resistance of protein breakdown is observed in septic and injured
rats [63,64,65], and IGF-1 fails to prevent pro-inflammatory
cytokine-induced myotube atrophy in vitro despite inactivation of
FoxO3 and decreased atrogin1 [66].
Myostatin, GDF-11 and TGF-b1
ICU patients showed a dramatic 95% lower myostatin and
likewise lower GDF-11 and TGF-b1 mRNA levels compared with
controls (Figure 8). To our knowledge, this is the first
demonstration that GDF-11 mRNA is expressed in human
skeletal muscle, and we show that GDF-11 responds similar to
the 90% sequence-similar myostatin. Our finding of substantially
higher Akt activation (Figure 4A and B) agrees well with the fact
that Akt activation blocks TGF-b signaling and its atrophic effects
in mice muscle [67]. Furthermore, the similar response of TGF-b1
and in particular GDF-11 is interesting, since negative regulators
of muscle mass similar to myostatin exist [68,69], and even though
studies of a muscle-specific conditional GDF-11 knock-out mice
indicate that GDF-11 does not regulate muscle size [70] TGF-b1
and other TGF-b superfamily members are candidate regulators
of muscle mass.
Limitations of the study
Overall, human studies in general and patient studies
specifically entail limitations including human heterogeneity. That
being said, most signaling pathways involved in skeletal muscle
remodeling in general and in sepsis have so far been established by
Table 4. Plasma amino acid concentrations (mmol/l).
Amino acid
Control subjects
(n=12)
ICU patients
(n=12) P-value
Isoleucine 32623 5 66 0.613
Leucine 89656 9 69 0.080
Lysine 236692 6 0 661 0.700
Methionine 29625 7 614 0.081
Phenylalanine 36619 0 616 0.007
Valine 177671 4 1 612 0.020
Arginine 61635 8 610 0.772
Histidine 61626 6 611 0.652
Proline 165683 5 5 667 0.017
Alanine 199616 3576104 0.160
Glutamine 516615 5766166 0.722
Glutamic acid 32633 0 64 0.795
Glycine 203616 254655 0.392
Serine 84655 8 69 0.026
Tyrosine 56626 3 616 0.702
Total AA 1976633 24696511 0.356
EAA 599616 6526106 0.635
BCAA 298613 245626 0.086
Values are means 6 SEM. AA: amino acids, EAA: essential AA, BCAA: branched
chain AA.
Total amino acids exclude asparagine, aspartic acid, cysteine, threonine and
tryptophan.
Significant p-values are bold and tendency p-values (0.10.p.0.05) are bold
italic.
doi:10.1371/journal.pone.0018090.t004
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PLoS ONE | www.plosone.org 7 March 2011 | Volume 6 | Issue 3 | e18090Figure 4. Substantially higher Akt-mTOR-S6k signaling in muscle of critically ill patients. Total (left), phosphorylated (middle) and
phosphorylated/total ratios (right) of Akt (A and B), mTOR (C), S6k (D), 4E-BP1 (E) and GSK3b (F) proteins in thigh skeletal muscle of critically ill
intensive care unit (ICU) patients compared with controls (CON). Representative blots are inserted. Phosphorylation status of Akt-mTOR-S6k were
higher in ICU vs. CON. Data are fold change in individual values relative to control mean. Each circle represents one subject (black: controls, white: ICU
patients) and the bar represents the mean value. * p,0.05, { p,0.01, { p,0.001.
doi:10.1371/journal.pone.0018090.g004
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is required as to whether these pathways are physiologically valid
and involved in humans [10,71], an attempt that has been done
seldom in ICU patients when it comes to skeletal muscle [23,72].
Regardless of a probably increased systemic inflammation in non-
surviving vs. surviving patients (Figure 1), a finding also seen in
larger studies [73,74], overall none of the differences in molecular
signaling between controls and ICU patients were driven by any
higher or lower expression or phosphorylation status in non-
survivor vs. survivor patients. Despite the variations in the patients’
diagnoses, ICU days at biopsy and clinical treatment (Table 1), our
data show rather small variation indicating that the patient
heterogeneity is of limited importance in the interpretation of the
present results. This is supported by previous studies on
heterogeneous ICU patients showing notable similarities in
numerous biochemical and physiological parameters regardless
of diagnosis and length of ICU stay [4,75,76], which indicate that
the metabolic sequelae in critical illness could be a common
response largely independent of admission diagnosis [4,76]. This
view is further substantiated by a recent microarray study on ICU
patients receiving insulin and corticosteroid therapy showing a
remarkably similar muscle transcript profile and the development
of a specific and clear muscle phenotype in these heterogeneous
patients [23], who are very similar to our patients with respect to
diagnoses, age (mean6SEM 6463 vs. 6465 years) and ICU days
at biopsy (763 vs. 662 days) (Table 1) [23].
Another limitation of our study is the lacking measures of
preferably sequential changes in muscle fiber cross-sectional area
(CSA) and muscle fractional protein synthesis and breakdown, as
done previously in patients with burns [37,38]. However, multiple
biopsies from each patient were impossible due to their critical
condition. The potential comparison between single time point
muscle fiber CSAs of ICU patients and controls is, however, not
without interpretational problems either. As detailed in table 1, 8 of
12 patients were current or previous abusers of alcohol, which in
itself causes muscle atrophy [77], and some patients had prior to
their ICU admission been hospitalized at other departments.
Accordingly, the comparison of fiber CSAs between patients and
controls would possibly show a lower mean fiber size of the patient
group and indicate muscle atrophy. Importantly, this comparison
will not,however, tellus whetherthis potentialdecreaseinfiberarea
occurred before or during ICU admission, and, additionally, the
considerable interpersonal variation in fiber size and number [78]
will certainly limit the use of this comparison. Still, the ICU patients
show some indications of muscle loss. The mean stay at the time of
the biopsy was 662 days, i.e. within 10 days after ICU admission,
where muscle atrophy is observed in some ICU patients [5,6].
The patients had high CRP and IL-6 levels and low serum
albumin levels (Table 3), which are part of the suggested diagnostic
criteria for cachexia [3], acknowledging that CRP and IL-6 mainly
are markers of inflammation. Despite these indices on muscle
wasting it has to be acknowledged that we do not know if our
patients experienced an active muscle loss or more stable state of
atrophy at the time of the biopsy. A more stable state of atrophy
could fit with our surprising observations of stimulated protein
synthesis pathways and somewhat inhibited protein degradation
pathways. Indirect evidence for muscle atrophy is the finding of a
good agreement between the atrogene profile observed in several
murine muscle atrophy models and the transcriptional response of
ICU patients similar to our patients [17,23]. On the other hand,
the ICU patients under the present study conditions recapitulate a
signaling pathway activity pattern, which in some animal models
[79,80], but not all [81], is related to the counteraction of disease-
related muscle loss.
Figure 5. Lower muscle and circulating IGF-1 in critically ill
patients. IGF-1Ea (A left) and IGF-1Ec (A right) mRNA expression in
thigh skeletal muscle of critically ill intensive care unit (ICU) patients
compared with controls (CON). mRNA data are fold change in individual
values relative to control mean. Plasma IGF-1 levels in ICU patients vs.
controls (B). Each circle represents one subject (black: controls, white:
ICU patients) and the bar represents the mean value. * p,0.05,
{ p,0.01.
doi:10.1371/journal.pone.0018090.g005
Figure 6. Correlation of insulin and Akt phosphorylation in
critically ill patients. To estimate the role of insulin in the activation
of Akt-mTOR-S6k signaling, we correlated insulin infusion doses at the
time of the biopsy with Akt phosphorylation (p-Akt) at threonine (T)
308. A moderate correlation between insulin doses and p-Akt was
demonstrated.
doi:10.1371/journal.pone.0018090.g006
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factors by e.g. phosphorylation [82] should be recognized as a main
regulatory event that was not examined in the present study. We
could not detect any total or phosphorylated FoxO proteins, which
may be due to FoxO protein content below our detection limit, since
low endogenous FoxO protein expression is present in mouse and rat
muscle cell lines [13,15,51] and rat skeletal muscle [14].
Figure 7. Divergent FoxO response and lower atrogene
expression in muscle of critically ill patients. FoxO1, 3 and 4 (A
left, middle and right), atrogin1 (B left) and MuRF1 (B right) mRNA
expression and MuRF1 protein content (C) in thigh skeletal muscle of
critically ill intensive care unit (ICU) patients compared with controls
(CON). FoxO1 mRNA was higher, whereas FoxO3 and its downstream
targets atrogin1 and MuRF1 were lower in ICU vs. CON. Representative
MuRF1 protein blot is inserted. Data are fold change in individual values
relative to control mean. Each circle represents one subject (black:
controls, white: ICU patients) and the bar represents the mean value.
*p ,0.05, { p,0.01, { p,0.001.
doi:10.1371/journal.pone.0018090.g007 Figure 8. Lower myostatin, GDF-11 and TGF-b1 mRNA in
muscle of in critically ill patients. Myostatin (A), GDF-11 (B) and
TGF-b1 mRNA expression in thigh skeletal muscle of critically ill
intensive care unit (ICU) patients compared with controls (CON). Data
are fold change in individual values relative to control mean. Each circle
represents one subject (black: controls, white: ICU patients) and the bar
represents the mean value. { p,0.01, { p,0.001.
doi:10.1371/journal.pone.0018090.g008
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In critically ill ICU patients compared with healthy controls, we
show substantially higher Akt-mTOR-S6k signaling and lower
FoxO3, atrogene and myostatin expression directed towards
stimulated muscle protein synthesis and somewhat inhibited
proteolysis. This is a surprising finding given the atrophic state
that the patients most likely are in. The observed divergent
response of the FoxO transcription factors suggests different
functional roles for the specific FoxO members in human skeletal
muscle. The lower FoxO3, atrogene and TGF-b family member
expression can be explained by the higher Akt activation. The
unexpected higher Akt-mTOR-S6k signaling may reflect a
stimulating effect of insulin therapy on protein synthesis signaling,
increased protein synthesis due to increased availability of
intracellular amino acids resulting from increased proteolysis
and/or an attempt to restore skeletal muscle mass. Importantly, it
is currently unsolved whether the observed molecular responses
reflect changes in muscle protein turnover and how they affect an
apparent dysfunctional muscle remodeling machinery. Further,
the present study suggests members of Akt-regulated pathways as
proteins of interest in future studies of the molecular mechanisms
of insulin on skeletal muscle protein metabolism in human critical
illness. Due to the study design limitations in critical illness
investigations, ex vivo muscle cell cultures from patient donors
may be one approach to mechanistically clarify the role of
hormones and nutrients on muscle mass regulating signaling.
Despite the recent questioning of the intensity of insulin treatment
of critical illness hyperglycemia [83], in a clinical perspective the
effects of insulin on muscle protein metabolism should be
considered and further investigated.
Supporting Information
Figure S1 Lower IL-1b mRNA expression in muscle of
critically ill patients. Interleukin-1b (IL-1b) (left) and mono-
cyte chemoattractant protein-1 (MCP-1) (right) mRNA expression
in thigh skeletal muscle of critically ill intensive care unit (ICU)
patients compared with controls (CON). Data are fold change in
individual values relative to control mean. Each circle represents
one subject (black: controls, white: ICU patients) and the bar
represents the mean value. * p,0.05.
(TIF)
Figure S2 Lower tenascin-C mRNA expression in mus-
cle of critically ill patients. Tenascin-C mRNA expression in
thigh skeletal muscle of critically ill intensive care unit (ICU)
patients compared with controls (CON). Data are fold change in
individual values relative to control mean. Each circle represents
one subject (black: controls, white: ICU patients) and the bar
represents the mean value.
(TIF)
Figure S3 Lower actinin3 mRNA expression in muscle
of critically ill patients. IL-6 receptor (IL-6R) (left) and
Figure 9. Muscle protein turnover signaling in critically ill ICU patients. Schematic overview of the results for circulating factors and muscle
protein turnover signaling in ICU patients under the present study conditions. Arrows at the different targets show the levels in ICU patients
compared with controls. Dotted lines depict that protein turnover was not determined. Abbreviations: 4E-BP1: eukaryotic translation initiation factor
4E binding protein 1, Akt: v-akt murine thymoma viral oncogene (aka PKB), BCAA: branched chain amino acids, CRP: C-reactive protein, GDF-11:
growth differentiation factor 11, GSK3b: glycogen synthase kinase 3b, IGF-1: insulin-like growth factor 1, IL: interleukin, MCP-1: monocyte
chemoattractant protein-1 (aka CCL2), mTOR: mammalian target of rapamycin, MuRF1: muscle ring finger 1, s6K: ribosomal protein S6 kinase, TGF-b:
transforming growth factor b, TNF-a: tumor necrosis factor a.
doi:10.1371/journal.pone.0018090.g009
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PLoS ONE | www.plosone.org 11 March 2011 | Volume 6 | Issue 3 | e18090actinin3 (right) mRNA expression in thigh skeletal muscle of
critically ill intensive care unit (ICU) patients compared with
controls (CON). Data are fold change in individual values relative
to control mean. Each circle represents one subject (black:
controls, white: ICU patients) and the bar represents the mean
value. { p,0.001.
(TIF)
Table S1 Primers used for RT-qPCR. Abbreviations:
RPLP0: acidic ribosomal protein P0, FoxO: Forkhead box O,
MuRF1: muscle ring finger 1, IGF-1: insulin-like growth factor,
GDF-11: growth differentiation factor 11, TGF-1b: transforming
growth factor 1 beta, TNF-a: tumor necrosis factor alpha, IL:
interleukin, IL-6R: IL-6 receptor, MCP-1: monocyte chemoat-
tractant protein 1.
(DOC)
Table S2 Antibodies used for Western blot. Antibodies
were diluted in 10% Odyssey blocking buffer (Li-Cor Biosciences)
in distilled water with 0.1% v/v Tween 20. All total and
phosphorylated protein pairs, except for mTOR, were detected
simultaneously on the same membrane. NA: Not applicable.
(DOC)
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